Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Phase 3

Terminated

• Conditions: Surgical Site Infection
• Interventions: Drug: Vancomycin; Drug: Delafloxacin; Drug: Linezolid; Drug: Piperacillin/Tazobactam; Drug: Tigecycline

• Registration Number: NCT04042077
• Lead Sponsor: Menarini Group

Brief Summary

The purpose of this study is to assess the efficacy and safety of delafloxacin administered as IV and oral formulation in comparison with Best Available Therapy (BAT) in patients with superficial or deep incisional surgical site infection following a cardiothoracic/related leg or abdominal surgery.

Detailed Description

This is a randomized, observer-blinded, active-controlled, parallel-group, multicenter, phase IIIb study for the treatment of incisional, superficial or deep, surgical site infection after cardiothoracic /related leg or abdominal surgery (i.e patients who are at risk of microbiologically resistant infections). IV to be switched to oral delafloxacin will be compared to treatments that represent the best available therapy (BAT) for either cardiothoracic/related leg or abdominal surgical site infection (SSI).

Approximately 600 male and female eligible patients will be randomly assigned in a 1:1 ratio to receive delafloxacin or BAT. For patients who are randomised to BAT, the investigator will choose one out of two treatments available (two available for the cardiothoracic/related leg and two available for abdominal SSI) as most appropriate for patient characteristics and local epidemiological pattern.

Duration of study depends on treatment duration (range: minimum 5 to maximum 14 days, as per Investigator's judgment) followed by visits up to 30 days after end of treatment.

Patients will be hospitalized from Screening (within 30 days from surgery) and will remain hospitalized until considered improved or cure as per Investigator's judgment.

Study Timeline

• Study First Submitted: 2019-07-29
• Study First Submitted QC: 2019-07-31
• Study First Posted: 2019-08-01
• Study Start: 2019-09-25
• Primary Completion: 2020-10-07
• Study Completion: 2020-10-28
• Status Verified: 2020-11
• Results First Submitted: 2021-08-06
• Results First Submitted QC: 2021-10-01
• Results First Posted: 2021-10-29
• Last Update Submitted: 2022-01-25
• Last Update Posted: 2022-02-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 268

Inclusion Criteria

• Male or female patients aged more than 18 years.
• Patients with a history of cardiothoracic / related leg or abdominal surgery, occurred within 30 days and no implant is left in place, and a diagnosis of superficial or deep SSI according to the CDC definition.
• The severity of infection requires an IV treatment and patient hospitalization according to the Investigator's judgment.

Read More

Exclusion Criteria

• Previous IV antimicrobial therapy exceeding 24-hour duration during 72 hours prior to first dose.
• Any infection expected to require systemic antimicrobial agents other than study treatment(s).
• Medical history of significant hypersensitivity or allergic reaction or contraindication to the study drugs
• Medical history of central nervous system (CNS) disorders
• Medical history of myasthenia gravis.
• Medical history of C. difficile diarrhea.
• Organ-space infection.
• Complicated Intra-Abdominal Infection (cIAI)
• Chronic or underlying conditions at site of infection that may complicate the assessment of clinical response or would interfere with SSI healing.
• Underlying disease leading to deep immunosuppressive status.
• End-stage renal disease, CrCl <15 mL/min.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Best Available Therapy	Piperacillin/Tazobactam	Cardiothoracic / related leg SSI * Vancomycin IV * Linezolid IV, with the option to switch to linezolid oral. In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice Abdominal SSI * Piperacillin/Tazobactam IV, OR * Tigecycline IV In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice.
Best Available Therapy	Linezolid	Cardiothoracic / related leg SSI * Vancomycin IV * Linezolid IV, with the option to switch to linezolid oral. In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice Abdominal SSI * Piperacillin/Tazobactam IV, OR * Tigecycline IV In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice.
Best Available Therapy	Vancomycin	Cardiothoracic / related leg SSI * Vancomycin IV * Linezolid IV, with the option to switch to linezolid oral. In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice Abdominal SSI * Piperacillin/Tazobactam IV, OR * Tigecycline IV In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice.
Best Available Therapy	Tigecycline	Cardiothoracic / related leg SSI * Vancomycin IV * Linezolid IV, with the option to switch to linezolid oral. In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice Abdominal SSI * Piperacillin/Tazobactam IV, OR * Tigecycline IV In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice.
Delafloxacin	Delafloxacin	Delafloxacin IV, with the option to switch to delafloxacin oral

Primary Outcome Measures

Name	Time	Method
Number of Participants With Clinical Success at Test Of Cure Visit	7-14 days after last dose	Clinical Success defined as the clinical response of "Cure" or "improved". Below the definitions: * Cure: The complete resolution of all baseline signs and symptoms of SSI; * Improved: two or more signs and/or symptoms (but not all) were considered resolved thus the patient had improved to an extent that no additional antibiotic treatment was necessary.

Secondary Outcome Measures

Name	Time	Method
Hospital Infection Related Length of Stay (IRLOS)	up to 14 days	Length of Stay since beginning of therapy till patient stabilization and considered suitable for hospital discharge
Hospital Length of Stay (LOS)	up to 45 days (Late Follow Up visit)	Length of Stay since Screening till actual hospital discharge
Number of Participants Eligible to Switch to Oral Formulation According to Blinded Observer's Assessment	up to 14 days	Blinded assessment based on patient stabilization and ability to tolerate OS diet. In particular, the following details had to be met: Systolic blood pressure normal/not clinically significant abnormal No infection related tachycardia Afebrile status; body temperature \<38°C for at least 24 hours\* WBC count normalized/not clinically significant abnormal Patient able to tolerate PO diet/to take PO treatment and no GI absorption problem; The measure counts only the participants eligible to switch, without taking into account the actually switched. Indeed, only linezolid in the BAT has an equivalent oral formulation suitable for the switch.
Microbiological Response	up to 14 days (End Of Treatment visit) and 7-14 days after last dose (Test Of Cure visit)	Documented or presumed eradication or persistence

Trial Locations

Locations (1)

Hospital Agostino Gemelli; 🇮🇹 Roma, Italy